CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NAMS

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

Phase 2
NewAmsterdam Pharma Co N.V. (NAMS)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '26
NAMSPhase 2

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Phase 2 Est. Readout

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Nov 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Dyslipidemias

View Full Landscape
Drug Information

Target Indication

Dyslipidemias

Clinical Trial

NCT06496243

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.